Resource Summary Report

Generated by nidm-terms on Aug 9, 2026

Brilliant Violet 421(TM) anti-human CD4

RRID:AB_10965645
Type: Antibody

Proper Citation

BioLegend Cat# 300532, RRID:AB_10965645

Antibody Information

URL: http://antibodyregistry.org/AB_10965645

Proper Citation: BioLegend Cat# 300532, RRID:AB_10965645

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC

Antibody Name: Brilliant Violet 421(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_10965645

Vendor: BioLegend

Catalog Number: 300532

Alternative Catalog Numbers: 300531

Record Creation Time: 20250820T025243+0000

Record Last Update: 20250820T144528+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD4.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

Ruan Z, et al. (2026) Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy. Med (New York, N.Y.), 7(4), 101026.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. iScience, 29(7), 116386.

Reinscheid M, et al. (2026) Acute and chronic infections drive distinct trajectories in human memory CD4+ T cell formation. Immunity, 59(5), 1272.

Suzuki K, et al. (2026) Targeting the ?v?5 Integrin Modifies the TGF?-Rich Tumor Microenvironment of Pancreatic Cancer. Cancer research, 86(15), 3801.

Burnell SEA, et al. (2025) OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. Cell reports methods, 5(12), 101251.

Chen Y, et al. (2023) Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell reports, 42(8), 112827.

Wilson JJ, et al. (2023) Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. iScience, 26(9), 107487.

Moguche AO, et al. (2017) Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell host & microbe, 21(6), 695.

Cornelius C, et al. (2016) Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine, 11, 58.